The PCCTC
@thepcctc.bsky.social
The Prostate Cancer Clinical Trials Consortium (PCCTC) translates scientific discoveries to improved standards of care. Visit pcctc.org to learn more.
PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...
Dr George on the Role of Radioligand Therapy in Prostate Cancer Management | OncLive
Daniel J. George, MD, discusses the potential of radioligand therapies for patients with prostate cancer and the evolution of this treatment paradigm.
www.onclive.com
November 13, 2025 at 2:20 PM
PCCTC investigator @dangeorgemd.bsky.social of Duke University discusses the role of radioligand therapy in prostate cancer management: www.onclive.com/view/dr-geor...
The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...
2026 Summer Internship Program — The PCCTC
The PCCTC plans on hiring three summer interns next year to support Data Management , Data Science , and Clinical Operations . The 10-week internships are full-time, paid, 100% remote, and working ...
www.pcctc.org
November 10, 2025 at 3:18 PM
The PCCTC plans on hiring three summer interns to support our Data Management, Data Science, and Clinical Operations teams. The 10-week internships are full-time, paid, 100% remote, and working hours are 9-5 EST. To learn more visit www.pcctc.org/news/2026-su...
Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...
Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum
Leading clinical oncology stakeholders gathered in San Diego on 4 November for a half-day symposium hosted by Biocom California in partnership with the UC San Diego Moores Cancer Center, titled Innova...
www.linkedin.com
November 6, 2025 at 1:41 PM
Prostate Cancer Clinical Trials Consortium (PCCTC) Innovation Featured at Biocom California’s “Innovations in Oncology Clinical Trial Design” Forum www.linkedin.com/pulse/prosta...
Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis - Prostate Cancer and Prostatic Diseases
Prostate Cancer and Prostatic Diseases - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis
www.nature.com
November 3, 2025 at 12:49 PM
Just published - DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis www.nature.com/articles/s41...
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
October 24, 2025 at 12:24 PM
The PCCTC's phase 2 study of talazoparib with or without enzalutamide in patients With metastatic castration-resistant prostate cancer and HRR mutations after progression on abiraterone acetate (TALENT) is now actively enrolling. To learn more visit clinicaltrials.gov/study/NCT068...
The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...
#usaclinicaltrials #brany #wcgirb #nct07103018 | K36 Therapeutics, Inc.
We’re thrilled to announce that our first site is officially activated for the KTX-2001 prostate cancer trial at #USAClinicalTrials in San Antonio, Texas! From regulatory packet submission to site ini...
www.linkedin.com
October 14, 2025 at 7:12 PM
The first site for the first-in-human KTX-2001 STRIKE-001 prostate cancer study has been activated at USA Clinical Trials (San Antonio, TX)—setting a PCCTC benchmark from reg packet distribution to site initiation. www.linkedin.com/posts/k36-th...
We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...
#lacog | LACOG - Latin American Cooperative Oncology Group
Today we had the pleasure of welcoming representatives from the Prostate Cancer Clinical Trials Consortium (PCCTC) to the LACOG Office, together with Dr. André Poisl Fay, Brazil Investigator Lead for ...
www.linkedin.com
October 7, 2025 at 4:52 PM
We are proud to collaborate with the Latin American Cooperative Oncology Group (LACOG) on innovative multicenter clinical studies like DORA and the IRONMAN Registry www.linkedin.com/embed/feed/u...
PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...
Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study
AbstractPurpose:. Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer with poor prognosis and limited treatment options. As NEPC aberrantly expresses delta-like ligand 3 (DL...
aacrjournals.org
October 1, 2025 at 4:20 PM
PCCTC investigators publish results from the phase 1b DeLLpro-300 study of tarlatamab in patients with neuroendocrine prostate cancer: aacrjournals.org/clincancerre...
Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...
ASCO 2025: Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry
ASCO 2025 metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI) from A multinational real-world analysis of the IRONMAN registry.
www.urotoday.com
September 24, 2025 at 6:17 PM
Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPI: A Multinational Real-World Analysis of the IRONMAN Registry. Story via UroToday: www.urotoday.com/conference-h...
PCCTC investigator Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial via Urology Times
www.urologytimes.com/view/rana-mc...
www.urologytimes.com/view/rana-mc...
Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial
Rana R. McKay, MD, FASCO, details the key efficacy and safety findings from the phase 2 COMRADE trial.
www.urologytimes.com
August 29, 2025 at 2:08 PM
PCCTC investigator Rana McKay, MD, outlines key findings from the phase 2 COMRADE trial via Urology Times
www.urologytimes.com/view/rana-mc...
www.urologytimes.com/view/rana-mc...
Reposted by The PCCTC
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
Rana R. McKay, MD, expands on key updates and knowledge gaps in prostate cancer management discussed at the Bridging the Gaps in Prostate Cancer meeting.
www.onclive.com
August 4, 2025 at 12:32 PM
Consensus Guidelines Needed to Further Optimize PARP Inhibition, Molecular Imaging, and ARPI Use in Prostate Cancer Management
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...
@ucsdhealth.bsky.social #ProstateCancer #PCSM
www.onclive.com/view/consens...
Reposted by The PCCTC
Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer!
cancer.wisc.edu/community-ou...
cancer.wisc.edu/community-ou...
Cancer Clear and Simple Podcast
Welcome to ‘Cancer Clear and Simple,’ the podcast dedicated to simplifying cancer. Join us as we discuss the world of cancer, breaking down complex concepts for our listening audience. One of our goal...
cancer.wisc.edu
July 25, 2025 at 1:11 PM
Such an honor and so much fun to join the Cancer Clear and Simple @uwhealth.bsky.social Carbone Cancer Center Podcast to discuss liquid biopsies in cancer!
cancer.wisc.edu/community-ou...
cancer.wisc.edu/community-ou...
PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...
Consensus Recommendations for PARP Inhibitor Use in Metastatic Prostate Cancer - Michael Carducci
Alan Bryce is joined by Michael Carducci to discuss consensus recommendations from the US Prostate Cancer Consensus Conference regarding PARP inhibitor testing and treatment strategies. Dr. Carducci e...
www.urotoday.com
July 22, 2025 at 2:35 PM
PCCTC investigator Michael A. Carducci, MD discusses consensus recommendations for PARP inhibitor use in metastatic prostate cancer with Alan Bryce, MD via UroToday: www.urotoday.com/video-lectur...
Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org
July 18, 2025 at 4:30 PM
Learn more about the PCCTC-managed PROMISE, a registry of prostate cancer patients participating in a research study to learn how genetic differences can affect patient outcomes: www.prostatecancerpromise.org
Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...
Emerging Trials and the Future of Biomarker-Driven Therapy in Metastatic Castration-Sensitive Prostate Cancer
Panelists discuss how emerging trials like AMPLITUDE (PARP inhibitors for BRCA mutations), PSMA-ADDITION (radioligand therapy), and CAPITELLO (AKT inhibitors for PTEN deficiency) are moving the field ...
www.onclive.com
July 10, 2025 at 2:11 PM
Esteemed PCCTC investigator Dr Rana McKay discusses the exciting developments in biomarker-driven therapy for metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/emergin...
Reposted by The PCCTC
Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!
Register now: surveys.mayoclinic.org/jfe/form/SV_...
Register now: surveys.mayoclinic.org/jfe/form/SV_...
July 9, 2025 at 5:35 PM
Mark Your Calendar! 🙌🏾🙌🏽🙌🏿 We’re headed to Lagos for the IRONMAN Conference from September 2nd through the 5th. This isn’t just an event, it’s a major milestone in global health and cancer research you won’t want to miss!
Register now: surveys.mayoclinic.org/jfe/form/SV_...
Register now: surveys.mayoclinic.org/jfe/form/SV_...
PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...
Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer
Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic...
www.onclive.com
July 2, 2025 at 3:03 PM
PCCTC investigator Dr Rana McKay and colleagues discuss personalizing treatment intensification in metastatic castration-sensitive prostate cancer via @onclive.bsky.social: www.onclive.com/view/persona...
Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...
Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial - Prostate Cancer and Prostatic Diseases
Prostate Cancer and Prostatic Diseases - Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial
www.nature.com
July 2, 2025 at 12:26 PM
Just published: Analysis from the TRANSFORMER prostate cancer study reveals baseline testosterone could be considered in the treatment selection process when bipolar androgen therapy is an option www.nature.com/articles/s41...
From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...
Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies
Radium-223 (Ra-223) has been approved since 2013 for men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases. Since then…
www.sciencedirect.com
June 30, 2025 at 5:59 PM
From PCCTC investigator Dr Rana McKay and colleagues, "Radium-223 in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Literature Review of Real-world Outcomes in Observational Studies," published in Eur Urol Oncol www.sciencedirect.com/science/arti...
Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...
ASCO 2025: Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Intensified by Androgen-Receptor Pathway Inhibitors (ARPI): A Multina...
ASCO 2025 metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI) from A multinational real-world analysis of the IRONMAN registry.
www.urotoday.com
June 26, 2025 at 1:04 PM
Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for Metastatic Hormone-Sensitive Prostate Cancer Intensified by Androgen-Receptor Pathway Inhibitors: A Multinational Real-World Analysis of the PCCTC-managed IRONMAN Registry www.urotoday.com/conference-h...
Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent
TALENT — The PCCTC
www.pcctc.org
June 16, 2025 at 11:38 PM
Learn more about TALENT, the PCCTC-managed study of talazoparib with or without enzalutamide in people with #prostatecancer who have previously received abiraterone (NCT06844383): www.pcctc.org/talent
#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
#CRPC #ProstateCancer #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/olapari...
#CRPC #ProstateCancer #ASCO25 @ascocancer.bsky.social
www.onclive.com/view/olapari...
Olaparib Plus Radium-223 Generates Superior rPFS in CRPC
Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.
www.onclive.com
June 3, 2025 at 9:20 PM
#ASCO25: PCCTC investigator Dr Rana McKay discusses the COMRADE study, "The combination of olaparib with radium-223 demonstrated feasibility, safety, and antitumor activity in patients with metastatic castration-resistant #prostatecancer with bone metastases”
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
June 3, 2025 at 1:30 PM
PCCTC study of a novel CTLA-engaging IO plus Lu177-PSA-617 therapy in patients with metastatic castration-resistant #prostatecancer (mCRPC) at #ASCO25 #MedIQASCO25 with @tiansterzhangmd.bsky.social. Clear activity and safe!
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
June 2, 2025 at 4:11 PM
Join us tomorrow (Tuesday) at #ASCO25 as PCCTC investigators present at the prostate cancer oral abstract session (Hall D1 and Live Stream)!
#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse ev...
www.jnj.com
June 1, 2025 at 2:19 PM
#ASCO25: PCCTC investigators Drs Karen Autio, Michael Schweizer, and Mark Stein contribute to first-in-human results for novel T-cell engager pasritamig (JNJ-78278343), showing early anti-tumor activity in #prostatecancer www.jnj.com/media-center...